Advances in Women's Health

Emerging Roles for Immunotherapy in HER2+ Breast Cancer

06.30.2020 - By ReachMDPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Guest: Sara Tolaney MD, MPH

What do we know now about the potential safety and tolerability of administering T-DM1 with pembrolizumab to patients with HER2+ breast cancer? Breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School Dr. Sara Tolaney explains these findings from her study that was presented at the 2020 ASCO Annual Meeting.

More episodes from Advances in Women's Health